Amgen Unusual Options Activity
Amgen Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.
拥有大量资金的鲸鱼对安进采取了明显的看淡立场。
Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.
查看安进（NASDAQ:AMGN）期权历史，我们检测到10笔交易。
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 50% with bearish.
如果考虑每个交易的具体情况，就可以准确地说40%的投资者持带看好预期的头寸，50%持看淡预期的头寸。
From the overall spotted trades, 2 are puts, for a total amount of $87,820 and 8, calls, for a total amount of $345,235.
从所有被发现的交易中，有2个看跌，总价值为87820美元，有8个看涨，总价值为345235美元。
Expected Price Movements
预期价格波动
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $270.0 to $345.0 for Amgen over the recent three months.
根据交易活动，显然，重要的投资者正针对安进最近三个月的价格区间270.0至345.0进行瞄准。
Insights into Volume & Open Interest
成交量和持仓量分析
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 240.4 with a total volume of 1,132.00.
在流动性和兴趣方面，安进期权今天的平均持仓量为240.4，总成交量为1132.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $270.0 to $345.0 over the last 30 days.
在下图中，我们可以跟踪过去30天内安进看涨和看跌期权的成交量和持仓量的发展情况，它们的执行价格范围为270.0至345.0。
Amgen Call and Put Volume: 30-Day Overview
安进看涨和看跌成交量：30天概述
Noteworthy Options Activity:
值得注意的期权活动：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 08/16/24 | $8.1 | $7.75 | $8.1 | $320.00 | $86.6K | 971 | 119 |
| AMGN | CALL | TRADE | BULLISH | 08/16/24 | $10.5 | $9.45 | $10.5 | $320.00 | $52.5K | 971 | 1 |
| AMGN | PUT | SWEEP | BEARISH | 07/19/24 | $5.05 | $4.75 | $4.93 | $317.50 | $50.3K | 80 | 0 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $9.6 | $9.4 | $9.4 | $320.00 | $47.0K | 971 | 65 |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $14.45 | $13.65 | $13.8 | $345.00 | $40.0K | 19 | 90 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看涨 | SWEEP | 看好 | 08/16/24 | $8.1 | $7.75 | $8.1 | $320.00 | $86.6K | 971 | 119 |
| AMGN | 看涨 | 交易 | 看好 | 08/16/24 | $10.5 | 9.45 | $10.5 | $320.00 | $52.5K | 971 | 1 |
| AMGN | 看跌 | SWEEP | 看淡 | 07/19/24 | $5.05 | $4.75 | $4.93 | $317.50 | $50.3K | 80 | 0 |
| AMGN | 看涨 | 交易 | 看淡 | 08/16/24 | 9.6 | 9.4美元 | 9.4美元 | $320.00 | $47.0千美元 | 971 | 65 |
| AMGN | 看涨 | SWEEP | 看好 | 01/17/25 | $14.45 | $13.65 | $13.8 | $345.00 | $40.0千美元 | 19 | 90 |
About Amgen
关于安进
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安进是生物技术制药领域的领导者。旗舰药物包括增加红细胞计数的艾普毕与阿拉尼许、增强免疫系统的奈帕姆和奈乌细胞移植因子、以及针对炎症性疾病的恩布瑞尔和欧特兹拉。安进在2006年推出了首个癌症治疗药物Vectibix，并推出了增强骨密度的药物Prolia/Xgeva（于2010年获批）和Evenity（于2019年获批）。对Onyx的收购增强了该公司在治疗肿瘤领域的药物组合，其中包括Kyprolis。最近推出的药物包括Repatha（降低胆固醇）、Aimovig（缓解偏头痛）、Lumakras（治疗肺癌）以及Tezspire（治疗哮喘）。2023年Horizon收购带来了几种罕见疾病药物，其中包括治疗甲状腺眼病的Tepezza。安进还拥有不断增长的生物类似物组合。
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
经过对安进周边期权交易的全面评估，我们转而更加详细地审查该公司。这包括对其当前的市场状态和表现的评估。
Amgen's Current Market Status
安进当前市场状态
- Currently trading with a volume of 869,379, the AMGN's price is down by -0.34%, now at $311.39.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 31 days.
- 成交量达869379股，安进的股价下跌了-0.34％，现在为311.39美元。
- RSI读数表明该股目前可能接近超买水平。
- 预期的收益发布还有31天。
Professional Analyst Ratings for Amgen
安进的专业分析师评级
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $336.0.
在过去的一个月中，有2位行业分析师分享了他们对这只股票的见解，提出了平均目标价336.0美元。
- An analyst from RBC Capital has decided to maintain their Outperform rating on Amgen, which currently sits at a price target of $332.
- An analyst from Argus Research persists with their Buy rating on Amgen, maintaining a target price of $340.
- 摩根资本（RBC Capital）的一位分析师决定维持对安进的跑赢大盘评级，目前的股价目标为332美元。
- 在安进上，雅运股份的一位分析师坚持买入评级，保持340美元的目标价。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期权交易具有更高的风险和潜在回报。精明的交易者通过不断学习、调整策略、监控多个因子和密切关注市场走势来管理这些风险。通过Benzinga Pro的实时提醒了解最新的安进期权交易。